公开(公告)号：US12233087B2

公开(公告)日：2025-02-25

申请号：US17055945

申请日：2019-05-16

Applicant: Emory University ,  The United States Government represented by The United States Department of Veterans Affairs

Inventor： Jack Arbiser ,  Lily Yang

IPC: A61K33/24 ,  A61K9/00 ,  A61K9/06 ,  A61K9/20 ,  A61K31/56 ,  A61K31/728 ,  A61P35/00

Abstract: This disclosure relates to palladium hyaluronic acid particles such as dibenzylideneacetone palladium hyaluronic acid particles. In certain embodiments, this disclosure relates to methods of managing cancer or angiogenic conditions using particles disclosed herein and pharmaceutical compositions comprising the same. In certain embodiments, an objective of this disclosure is hyaluronic acid targeting of CD44, a tumor stem cell marker. In certain embodiments, this disclosure relates to treatment with hyaluronic acid palladium particles disclosed herein for depleting CD44 cells.

公开(公告)号：US12226423B2

公开(公告)日：2025-02-18

申请号：US17852142

申请日：2022-06-28

Applicant: Virginia Commonwealth University ,  Durect Corporation ,  The United States Government as Represented by the Department of Veterans Affairs

Inventor： Shunlin Ren ,  Leyuan Xu ,  Yanxia Ning ,  Jin Koung Kim ,  WeiQi Lin ,  Andrew R. Miksztal ,  Hongwei Wu ,  Min L. Lee

IPC: A61K31/565 ,  A61K8/63 ,  A61K8/73 ,  A61K9/00 ,  A61K9/19 ,  A61K31/575 ,  A61K31/724 ,  A61K47/10 ,  A61K47/40 ,  A61P1/16 ,  A61P3/06 ,  A61P17/06 ,  A61P31/04 ,  A61Q19/00 ,  C07J31/00

Abstract: Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol/high lipids, and various inflammatory diseases and conditions.

公开(公告)号：US20250050047A1

公开(公告)日：2025-02-13

申请号：US18719658

申请日：2022-12-12

Applicant: The United States Government as represented by the Department of Veterans Affairs ,  The Board of Trustees of the University of Illinois

Inventor： Israel Rubinstein ,  Andrea Benedetti ,  Alexander Twaddle ,  Grace Dyer ,  Kimberlee Wilkens ,  Lara Nammari

IPC: A61M16/06 ,  A61M16/00

Abstract: A gas flow control device uses the curvature of nasal cannula or other tubes conveying the gas to control an actuator movable between two different configurations to permit or prevent gas flow. Curvature of the nasal cannula is measured by a sensor whose electrical resistance changes in response to the curvature of the sensor. The sensor is mounted on the cannula. Signals from the sensor are transmitted to a controller, which moves the actuator when the curvature exceeds or falls below a threshold value as measured by the change in electrical resistance of the sensor. The device finds use in oxygen therapy, where oxygen flow to a patient is cut off when the sensor indicates non-compliant behavior by the patient, indicating release of oxygen into the environment and causing a potential fire hazard.

公开(公告)号：US20250032484A1

公开(公告)日：2025-01-30

申请号：US18715993

申请日：2022-12-02

Applicant: The United States Government as represented by the Department of Veterans Affairs ,  MARY HITHCOCK MEMORIAL HOSPITAL ,  THE TRUSTEES OF BOSTON UNIVERSITY

Inventor： Brian Shiner ,  Jaimie L. Gradus

IPC: A61K31/4985 ,  A61K31/4188 ,  A61K31/439 ,  A61K31/454 ,  A61K31/7072 ,  A61K45/06 ,  A61P25/00 ,  A61P25/32

Abstract: The invention generally relates to methods of treating psychiatric disorders using one or more compounds selected from pibrentasvir, glecaprevir, velpatasvir, ledipasvir, and sofosbuvir, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US20250025495A1

公开(公告)日：2025-01-23

申请号：US18775053

申请日：2024-07-17

Applicant: UNM Rainforest Innovations ,  THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS

Inventor： Henry C. Lin ,  Nancy L. Kanagy ,  Aleksandr Birg ,  Sudha Singh ,  Cristina N. Coffman

IPC: A61K33/06 ,  A61K31/198

Abstract: The present invention is directed to compositions which comprise at least two components comprising a magnesium compound and glutamine, often three components, a high bioavailability magnesium salt or chelate, a low bioavailability magnesium salt or chelate and glutamine (often as a neutral species or as a zwitterionic salt). It has been discovered unexpectedly that the compositions which contain these two or three components are effective at treating/inhibiting metabolic syndrome and its symptomology, including insulin resistance, and related disease states and/or conditions. Compositions according to the present invention also inhibit/treat dysbiosis such that the gut microbiome is maintained or returns to normal.

公开(公告)号：US20250017915A1

公开(公告)日：2025-01-16

申请号：US18710037

申请日：2022-11-15

Applicant: The Board of Trustees of the University of Illinois ,  The United States Government as Represented by The Department of Veterans Affairs

Inventor： Gregory R. Thatcher ,  Ajay Rana ,  Rui Xiong ,  Daniel Principe ,  Yangfeng Li

IPC: A61K31/444 ,  A61K39/395 ,  A61P35/00

Abstract: In accordance with the purpose(s) of the present disclosure, described herein are methods for treating cancer associated with a Ras mutation in a subject in need of treatment comprising administering to the subject an effective amount of a compound of formula I as described herein or a pharmaceutically acceptable salt thereof. The compounds described herein have improved efficacy compared to the benchmark BET inhibitor JQ-1 and comparable efficacy to high dose JQ-1 with respect to the treatment of PDAC. In one aspect, the compounds are administered in combination with an effective amount of an immune checkpoint inhibitor such as, for example, PD-1/PD-L 1 inhibitor, a CTLA-4 inhibitor, or a combination thereof.

公开(公告)号：US20240409895A1

公开(公告)日：2024-12-12

申请号：US18424086

申请日：2024-01-26

Applicant: The United States Government As Represented By The Department Of Veterans Affairs ,  The Regents Of The University Of California

Inventor： Robert L. Raffai ,  Tuan Anh Phu ,  Ngan Khanh Vu ,  Martin Ng ,  Laura Bouchareychas

IPC: C12N5/0786

Abstract: Disclosed are method of producing IL-4 exposed M2 macrophage exosomes comprising culturing macrophage or macrophage precursor cells with IL-4 in culture media, and isolating exosomes from the culture media, wherein the isolated exosomes are IL-4 exposed M2 macrophage exosomes enriched with miR-21, miR-99a, miR-146b and miR378a. Disclosed are methods of reprogramming macrophages and/or adipocytes comprising exposing the macrophages and/or adipocytes to IL-4 exposed M2 macrophage exosomes, wherein immune and/or metabolic properties are altered in the macrophages and/or adipocytes. Methods of treating with IL-4 exposed M2 macrophage exosomes.

公开(公告)号：US12161655B2

公开(公告)日：2024-12-10

申请号：US17273034

申请日：2019-09-03

Applicant: Paratek Pharmaceuticals, Inc. ,  United States Government as Represented by the Department of Veterans Affairs

Inventor： Michael Henry Cynamon ,  Michael P. Draper ,  Judith N. Steenbergen ,  S. Ken Tanaka

IPC: A61K31/65 ,  A61P31/06

Abstract: The present invention provides methods of treating mycobacterial infections or mycobacterial diseases by administering a tetracycline compound, e.g., omadacycline, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240342139A1

公开(公告)日：2024-10-17

申请号：US18615330

申请日：2024-03-25

Applicant: The United States Government As Represented By the Department of Veterans Affairs

Inventor： Brian Kraemer

IPC: A61K31/429 ,  A61P25/28 ,  C07C317/14 ,  C07D231/14 ,  C07D277/40 ,  C07D277/60 ,  C07D403/06 ,  C07D409/06 ,  C07D513/04 ,  C07D513/10 ,  C07D513/14

CPC classification number: A61K31/429 ,  A61P25/28 ,  C07C317/14 ,  C07D231/14 ,  C07D277/40 ,  C07D277/60 ,  C07D403/06 ,  C07D409/06 ,  C07D513/04 ,  C07D513/10 ,  C07D513/14

Abstract: The present disclosure is concerned with substituted thiochromenothiazole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds in the treatment of neurodegenerative disorders associated with dysregulation of MSUT2 signaling such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), motor neuron disease, ataxia, progressive supranuclear palsy (PSP), multiple system atrophy, corticobasal degeneration (CBD), argyrophilic grain disease (AGD), Pick's disease (PiD), dementia, Huntington's disease (HD), primary age-related tauopathy (PART), and aging-related tau astrogliopathy (ARTAG). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US20240335503A1

公开(公告)日：2024-10-10

申请号：US18579252

申请日：2022-07-15

Applicant: The United States Government as represented by the Department of Veterans Affairs

Inventor： Andrew Tan

IPC: A61K38/15 ,  A61K45/06 ,  A61P25/02 ,  A61P25/04

CPC classification number: A61K38/15 ,  A61K45/06 ,  A61P25/02 ,  A61P25/04

Abstract: The invention generally relates to methods of treating spasticity and/or neuropathic pain using known romidepsin and pharmaceutical compositions comprising same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.